Allianz Asset Management GmbH Has $47.47 Million Stake in Qiagen N.V. $QGEN

Allianz Asset Management GmbH increased its holdings in Qiagen N.V. (NYSE:QGEN) by 366.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 994,697 shares of the company’s stock after buying an additional 781,561 shares during the period. Allianz Asset Management GmbH owned 0.45% of Qiagen worth $47,470,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of Qiagen in the first quarter valued at approximately $31,000. Farther Finance Advisors LLC raised its position in Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares in the last quarter. Hilltop National Bank acquired a new position in Qiagen during the second quarter valued at approximately $66,000. ANTIPODES PARTNERS Ltd acquired a new position in Qiagen during the first quarter valued at approximately $94,000. Finally, GAMMA Investing LLC raised its position in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after purchasing an additional 1,425 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Up 0.3%

Shares of NYSE:QGEN opened at $48.29 on Friday. The company has a fifty day moving average of $47.00 and a 200-day moving average of $45.77. The company has a market capitalization of $10.73 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts predict that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

QGEN has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research report on Wednesday, October 8th. Cowen restated a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. UBS Group boosted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Finally, Barclays set a $53.00 price objective on shares of Qiagen and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Three analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.